Biography
Dr. Marion Peters is a Professor of Medicine and holds the John V. Carbone, M.D., Endowed Chair in Medicine. She is also Chief of Hepatology Research. Dr. Peters is especially interested in the immunology of chronic liver diseases, particularly viral and autoimmune hepatitis. Her research activities include studies of transgenic mouse models of liver specific T cell responses, HIV and HCV coinfection, and alcohol and HCV infection.
Dr. Peters graduated from Melbourne University Medical School, Australia in 1972. She trained in gastroenterology, hepatology and immunology at St. Vincent's Hospital, Melbourne, University of Southern California and National Institutes of Health. She was Chief of Hepatology and medical director of Liver Transplantation at Washington University School of Medicine from 1985 to 1998.
Education
Melbourne University Medical School, Melbourne, Australia, M.B.B.S., 1972, Medicine
St. Vincent's Hospital Medical School, Melbourne, Australia, Medicine
Melbourne University, M.D., 1991, Medicine/Immunology
1973-76 Resident and Registrar in Internal Medicine, St.Vincent's Hospital, Melbourne, Australia
1976-77 Clinical Research Registrar to Dr. I. R. Mackay, Royal Melbourne Hospital and The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
Board Certifications
American Board of Internal Medicine, Internal Medicine
Clinical Expertise
Alcoholic Liver Disease
Autoimmune Hepatitis
Benign Liver Tumors
Cirrhosis
Fulminant Hepatic Failure
Hepatitis B
Hepatitis C
Hepatocellular Carcinoma (Liver Cancer)
Live Donor Liver Transplantation
Liver Transplantation
Nonalcoholic Fatty Liver Disease
Primary Biliary Cirrhosis
Primary Sclerosing Cholangitis
Clinical Trials
- Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects (NCT00991289)Related Conditions: HIV/AIDS, Hepatitis C, Hepatitis A, Hepatitis| Start Date: | End Date:
- A Comparison of Adefovir and Tenofovir for the Treatment of Lamivudine-Resistant Hepatitis B Virus in People With HIV (NCT00033163)Related Conditions: HIV/AIDS, Hepatitis B, Hepatitis A, Hepatitis| Start Date: | End Date:
Program Affiliations
UCSF Liver Center
Member, UCSF Immunology Graduate Program
UCSF Helen Diller Family Comprehensive Cancer Center
Grants and Funding
- UCSF Liver Center | NIH | 1985-07-01 - 2023-05-31 | Role: Co-Investigator
- NRSA Hepatology Training Grant | NIH | 2001-12-01 - 2022-06-30 | Role: Co-Principal Investigator
- HIV status and reproductive aging affect liver fibrosis in HIV/HCV infected women | NIH | 2010-03-15 - 2013-02-28 | Role: Principal Investigator
- General Clinical Research Center | NIH | 1974-12-01 - 2009-03-31 | Role: Co-Investigator
- GENERAL CLINICAL RESEARCH CENTER | NIH | 1974-10-01 - 2009-03-31 | Role: Co-Investigator
- HCV &ALCHOOL-- EPIDEMIOLOGY &HOST-VIRUS CORRELATES | NIH | 2000-09-30 - 2006-07-31 | Role: Principal Investigator
- INTESTINAL IMMUNE RESPONSE INFLAMMATORY BOWL DISEASE | NIH | 1995-09-30 - 2001-08-31 | Role: Principal Investigator
- INTESTINAL IMMUNE RESPONSE IN INFLAMMATORY BOWEL DISEASE | NIH | 1991-06-25 - 1995-10-31 | Role: Principal Investigator
Research Narrative
My major interest is in viral hepatitis and the role of the host immune response. My work focuses on interactions among alcohol use, cannabis use and HIV co-infection on fibrotic outcomes of HCV infection. We are currently evaluating the predictors of progression of liver disease in HIV and HCV coinfected women within the Women's Interagency HIV Study (WIHS): the role of alcohol, cannabis, HIV status and control as well as reproductive aging on the severity and rate of progression of liver disease.
We are also studying adherence to antiretroviral therapy in HIV/HCV co-infected women and on HCV-specific and innate immune responses in persons co-infected with HCV and HIV. I work within the AIDS Clinical Trial Group to develop clinical trials in viral hepatitis and HIV and within the Women's Interagency HIV Study (WIHS) to examine predictors of liver-related morbidity and mortality in a cohort of women with HIV/HCV infection.
Research Interests
Liver Injury and Repair
Viral hepatitis and the role of the host immune response.
Publications
- Treatment Algorithm for Managing Chronic Hepatitis B Virus Infection in the United States: 2021 Update.| | PubMed
- Decreases in markers of monocyte/macrophage activation after hepatitis C eradication in HIV/hepatitis C virus coinfected women.| | PubMed
- Risk of HCC With Hepatitis B Viremia Among HIV/HBV-Coinfected Persons in North America.| | PubMed
- A Multiancestry Sex-Stratified Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus.| | PubMed
- Hepatotoxicity and Liver-Related Mortality in Women of Childbearing Potential Living With Human Immunodeficiency Virus and High CD4 Cell Counts Initiating Efavirenz-Containing Regimens.| | PubMed
- Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015.| | PubMed
- Retrospective-prospective study of safety and efficacy of sofosbuvir-based direct-acting antivirals in HIV/HCV-coinfected participants with decompensated liver disease pre- or post-liver transplant.| | PubMed
- Correction: Multi-ancestry fine mapping of interferon lambda and the outcome of acute hepatitis C virus infection.| | PubMed
- Multi-ancestry fine mapping of interferon lambda and the outcome of acute hepatitis C virus infection.| | PubMed
- Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic Hepatitis B Virus Infection: Systematic Review and Meta-analysis.| | PubMed